Open Access25-Hydroxyvitamin D3-1α-hydroxylase Expression in Normal and Malignant Human Colon
Author(s) -
Giovanna Bises,
Enikö Kállay,
Tina Weiland,
Friedrich Wrba,
E. Wenzl,
Elisabeth Bonner,
Stefan Kriwanek,
Peter Obrist,
Heide S. Cross
Publication year - 2004
Publication title -
journal of histochemistry and cytochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.971
H-Index - 124
eISSN - 1551-5044
pISSN - 0022-1554
DOI - 10.1369/jhc.4b6271.2004
Subject(s) - autocrine signalling , paracrine signalling , immunofluorescence , vitamin d and neurology , colorectal cancer , biology , messenger rna , calcitriol receptor , chemistry , cancer research , pathology , endocrinology , microbiology and biotechnology , medicine , receptor , cancer , antibody , biochemistry , immunology , gene
1,25-dihydroxyvitamin D(3) has anti-mitotic, pro-differentiating, and pro-apoptotic activity in tumor cells. We demonstrated that the secosteroid can be synthesized and degraded not only in the kidney but also extrarenally in intestinal cells. Evaluation of 1,25-dihydroxyvitamin D(3)-synthesizing CYP27B1 hydroxylase mRNA (real-time PCR) and protein (immunoblotting, immunofluorescence) showed enhanced expression in high- to medium-differentiated human colon tumors compared with tumor-adjacent normal mucosa or with colon mucosa from non-cancer patients. In high-grade undifferentiated tumor areas expression was lost. Many cells co-expressed CYP27B1 and the vitamin D receptor. We suggest that autocrine/paracrine antimitotic activity of 1,25-dihydroxyvitamin D(3) could prevent intestinal tumor formation and progression.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom